Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 32Leukemia 21Lymphoma 15Prostatic Neoplasms 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 10Lymphoma, Large B-Cell, Diffuse 9Leukemia, Monocytic, Acute 8Recurrence 7Lymphoma, Mantle-Cell 7Leukemia, Myelomonocytic, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia, Erythroblastic, Acute 7Congenital Abnormalities 7Myelodysplastic Syndromes 6Leukemia, Megakaryoblastic, Acute 6Lymphoma, Large-Cell, Immunoblastic 5Hodgkin Disease 4Burkitt Lymphoma 4Breast Neoplasms 4Blast Crisis 4Multiple Myeloma 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Leukemia, Biphenotypic, Acute 2HIV Infections 2Drug-Related Side Effects and Adverse Reactions 2

Interventions

venetoclax 1olutasidenib 1magrolimab 1cc-486 1Mitoxantrone 1Etoposide 1Cytarabine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Myeloid Malignancies × Mitoxantrone × Clear all
NCT04778410 2025-03-20

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

Gilead Sciences

Phase 2 Terminated
54 enrolled 26 charts

Myeloid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡